Reversal of anticoagulation in intracranial hemorrhage. … one of these should be used, along with vitamin K: 4-factor PCC – We generally give 4-factor PCC ( Kcentra in the United States and Japan; Beriplex or Octaplex in Canada; Octaplex, Cofact, or Proplex in many …. Management of warfarin-associated bleeding or supratherapeutic INR.3. Visually inspect the prepared Kcentra for particulate matter and/or discoloration. Do not use if either is observed. 4. The nurse should attach tubing to Kcentra bag and administer via IV pump at the maximum rate of 8.4mL/min (~500mL/hr) 5. After the infusion of Kcentra is complete, remove the empty bag and hang a 50mL NS bag using the same ... Call the Kcentra Hotline at 1-855-452-3687; Adverse reactions: If your patient is having an adverse reaction to Kcentra, contact or have them contact CSL Behring Pharmacovigilance at 1-866-915-6958. For any other concern related to treatment with Kcentra, you can call the Kcentra Hotline at 1-855-452-3687 to speak with them about how to proceedK-Centra contains trace amounts of heparin (to mitigate thrombotic potential) and should not be used in bleeding patients with active or recent (last 100 days) heparin-induced thrombocytopenia (HIT). In this instance, please contact pharmacy to discuss possible use of the alternative procoagulant FEIBA for reversal. rFVIIa (if refractory to ...KCENTRA ®, Prothrombin Complex Concentrate (Human), is a blood coagulation factor replacement product indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA—eg, warfarin) therapy in adult patients with acute major bleeding or the need for urgent surgery or other invasive procedure. K-centra. (Kontaktní a poradenská centra) Kontaktní centra hrají důležitou roli zejména v prevenci škodlivých následků užívání drog – snaží se zmírnit dopad a škody způsobené drogami. Jde o takzvaná „nízkoprahová zařízení“ – podmínky jsou nastaveny tak, aby sem mohl přijít každý, kdo potřebuje pomoc a je ...Figure 1. The vitamin K cycle and its link to carboxylation of glutamic acid residues on vitamin K–dependent coagulation proteins. Vitamin K 1 obtained from food sources is reduced to vitamin KH 2 by a warfarin-resistant vitamin K reductase.Jul 11, 2017 · Kcntra costs roughly $1.27 per unit. Kcentra® is dosed according to Factor IX potency and is individualized based on the patient’s baseline International Normalized Ratio (INR) and body weight. The cost of Kcentra® is $1.27 per unit; a single dose of Kcentra® for an 80 kg patient costs $5,080. A single 90 µg/kg dose of Factor VII to a 80 ... The Use of Kcentra in the Reversal of Coagulopathy of Chronic Liver Disease. J Pharm Pract2018 Feb;31 (1):120-125. doi: 10.1177/0897190017696952. Epub 2017 Mar 15. We aim to describe our experience with the four-factor prothrombin complex concentrates (4F-PCC) Kcentra at differing doses in patients with liver cirrhosis requiring emergent ...Kcentra Speak with a Kcentra Hotline 1-855-4KCENTRA (1-855-452-3687) Hotline TOLL-FREE: www.Kcentra.com 7. Place the Kcentra vial on an even and fi rm surface. Invert the diluent vial with the Mix2Vial set attached and push the spike of the transparent adapter end straight down through the Kcentra vial stopper. The diluent will automatically fl ...KCENTRA is contraindicated in patients with known anaphylactic or severe systemic reactions to KCENTRA or any of its components (including heparin, Factors II, VII, IX, X, Proteins C and S, Antithrombin III and human albumin). KCENTRA is also contraindicated in patients with disseminated intravascular coagulation. (Kcentra) Clinical Recommendations for Use April 2015 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. Medical question support Kcentra Hotline representatives are trained to answer medical and treatment questions, which differentiates them from other hotlines that are strictly for product information and ordering/reimbursement support. Treating a patient and want to talk with a healthcare professional? Call the Kcentra Hotline at 1-855-452-3687Dec 27, 2012 · Kcentra Marketing Approval Date: 12/13/2013 Approved Labeled Indication: Urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding or need for an urgent surgery/invasive procedure. Exclusivity End Date: May 16, 2023 · Kcentra Reconstitution Instructions. Ensure that the KCENTRA vial and diluent vial are at room temperature. Remove flip caps from the KCENTRA and diluent vials. Wipe the stoppers with the alcohol swab provided and allow to dry prior to opening the Mix2Vial package. Open the Mix2Vial package by peeling off the lid (Fig. 1). 380-800 units FII/500 units of Kcentra Non-activated form Units of FVII 10 ≤ 52.5 IU/mL (No more than 35 units/100 Factor IX units) -240 IU/mL 200-500 units FII/500 units of Kcentra Activated form Units of FIX 100-150 IU/mL 10-60 IU/mL 400-620 units FII/500 units of Kcentra Non-activated form Units of FX Individuals using assistive technology may not be able to fully access the information contained in this file. For assistance, please call 800-835-4709 or 240-402-8010, extension 1. KCENTRA, Prothrombin Complex Concentrate (Human), is a blood coagulation factor replacement product indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with: acute major bleeding or.Concentration: Final concentration in Factor IX units will range from 20–31 units/mL when reconstituted. Actual potency is listed on carton. If patient is to receive multiple vials, may pool contents; use a separate unused Mix2Vial transfer set for each vial. Administration should begin promptly or within 4 hrs of reconstitution. KCENTRA ®, Prothrombin Complex Concentrate (Human), is a blood coagulation factor replacement product indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA—eg, warfarin) therapy in adult patients with acute major bleeding or the need for urgent surgery or other invasive procedure ...4-factor PCC (Kcentra) If INR 2-4: 25 units/kg (not to exceed 2500 units) If INR 4-6: 35 units/kg (not to exceed 3500 units) If INR > 6: 50 units/kg (not to exceed 5000 units) References: 1. Beshay JE, Morgan H, Madden C, Yu W, Sarode R. Emergency reversal of anticoagulation and antiplatelet therapies in neurosurgical patients. Dec 4, 2017 · K-Centra contains trace amounts of heparin (to mitigate thrombotic potential) and should not be used in bleeding patients with active or recent (last 100 days) heparin-induced thrombocytopenia (HIT). In this instance, please contact pharmacy to discuss possible use of the alternative procoagulant FEIBA for reversal. rFVIIa (if refractory to ... Kcentra® is a 4-factor PCC that is FDA approved for the reversal of warfarin. Kcentra® contains factors II, VII, IX, and X but also contain other components like heparin, Antithrombin III, protein C, and Protein S. Kcentra is dosed based off of the Factor IX content and this can vary to a small extent from one lot to the next.We would like to show you a description here but the site won’t allow us.of thromboembolic events. KCENTRA was not studied in subjects who had a throm-botic or thromboembolic (TE) event within the prior 3 months. KCENTRA may not be suitable in patients with thromboembolic events in the prior 3 months. (5.2) • KCENTRA is made from human blood and may carry a risk of transmitting infectious KCentra as a means to reverse apixaban or rivaroxaban, against a targeted approach using Andexanet Alfa, which is associated with significantly more cost but which may be more efficacious given its mechanism of action. References:1-4 1. Babilonia K, Trujillo T. The role of prothrombin complex concentrates in reversal of target specific ... A 4-factor prothrombin complex concentrate (4F-PCC, Kcentra®) was recently approved in the United States for the reversal of vitamin K antagonist-associated major bleeding, but it is often used to reverse coagulopathy in patients with liver disease (LD). This single-center, retrospective study analyzed the efficacy and safety of 4F-PCC ...Kcentra is a 4 factor PCC from CSL Behring, containing non-activated factors II, VII, IX and X. The current FDA indications for Kcentra is for reversal of vitamin K dependent procoagulant factors II, VII, IX and X induced by oral vitamin K antagonists such as warfarin or coumadin. There are case reports of Kcentra use in FXa DOAC reversal. KCentra as a means to reverse apixaban or rivaroxaban, against a targeted approach using Andexanet Alfa, which is associated with significantly more cost but which may be more efficacious given its mechanism of action. References:1-4 1. Babilonia K, Trujillo T. The role of prothrombin complex concentrates in reversal of target specific ...In September 2018, the Pharmacy and Therapeutics Committee approved a new protocol for Emergent Vitamin K Antagonist (Warfarin) reversal via fixed dose Kcentra (PCC). We will go live with this protocol on January 22, 2019 .Kcentra (human prothrombin complex concentrate) is the first nonactivated 4-factor prothrombin complex concentrate for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA) therapy (eg, warfarin) in adult patients with acute major bleeding. Each year, approximately 3 to 4 million people in the ...KCENTRA is contraindicated in patients with known anaphylactic or severe systemic reactions to KCENTRA or any of its components (including heparin, Factors II, VII, IX, X, Proteins C and S, Antithrombin III and human albumin). KCENTRA is also contraindicated in patients with disseminated intravascular coagulation.If idarucizumab is not available, consider 4-factor PCC (KCentra) 2000 units NOTE: idarucizumab will likely correct aPTT and plasma-diluted thrombin time but the correlation of lab results with improved outcomes is not established NOTE: Plasma dabigatran concentrations can increase more than 12-24 hours after idarucizumab, However, there is limited data on the efficacy and adverse effects of the commercial Kcentra used in these patients. Kcentra, the only approved PCC in the USA, is FDA approved for urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA) therapy in adult patients with acute major bleeding or need for an ...Kcentra is contraindicated in patients with known anaphylactic or severe systemic reactions to Kcentra or any of its components (including heparin, Factors II, VII, IX, X, Proteins C and S, Antithrombin III and human albumin). Kcentra is also contraindicated in patients with disseminated intravascular coagulation.The primary outcome was coagulopathy reversal, defined as a post-Kcentra INR of This study included 31 patients with acute or chronic liver failure and 54 patients without liver failure. Both groups of patients were similar at baseline, except those that had liver failure were younger (58 vs 70 years, P < 0.01).May 3, 2015 · Kcentra 072913 final. Kcentra: A 4-Factor Prothrombin Concentrate Sylvia Doyle, Pharm.D. Elva Angelique Van Devender, Ph.D., Pharm.D., BCPS Legacy Good Samaritan Emergency Department. May 3, 2015 2 Background Kcentra is the first four-factor prothrombin complex concentrate approved for the urgent reversal of vitamin K antagonist-related major ... Reversal of anticoagulation in intracranial hemorrhage. … one of these should be used, along with vitamin K: 4-factor PCC – We generally give 4-factor PCC ( Kcentra in the United States and Japan; Beriplex or Octaplex in Canada; Octaplex, Cofact, or Proplex in many …. Management of warfarin-associated bleeding or supratherapeutic INR.Kcentra Speak with a Kcentra Hotline 1-855-4KCENTRA (1-855-452-3687) Hotline TOLL-FREE: www.Kcentra.com 7. Place the Kcentra vial on an even and fi rm surface. Invert the diluent vial with the Mix2Vial set attached and push the spike of the transparent adapter end straight down through the Kcentra vial stopper. The diluent will automatically fl ... For example, a Kcentra® 500 unit vial can contain 400-620 units and a 1000 unit vial can contain 800-1240 units [5]. Most hospitals are required to bill based on exact units administered, so pharmacies often need to adjust Kcentra® orders to reflect the units that will be administered. Kcentra is currently used in the reversal of blood thinners like warfarin in patients with bleeding or who need immediate surgery. It is believed it will also help stop severe bleeding in people with traumatic injuries. This study will be conducted in 3 US cities, including Portland. People will be enrolled shortly after injury and before ...Kcentra is a blood coagulation factor replacement product. Kcentra is used to quickly reverse the effects of a blood-thinning medicine (such as warfarin ) during a major bleeding episode, or when there is a need for emergency surgery or invasive medical procedure.KCENTRA is contraindicated in patients with known anaphylactic or severe systemic reactions to KCENTRA or any of its components (including heparin, Factors II, VII, IX, X, Proteins C and S, Antithrombin III and human albumin). KCENTRA is also contraindicated in patients with disseminated intravascular coagulation. KCENTRA ®, Prothrombin Complex Concentrate (Human), is a blood coagulation factor replacement product indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA—eg, warfarin) therapy in adult patients with acute major bleeding or the need for urgent surgery or other invasive procedure ...Apr 12, 2023 · What is Kcentra? Kcentra is a blood coagulation factor replacement product. Kcentra is used to quickly reverse the effects of a blood-thinning medicine (such as warfarin) during a major bleeding episode, or when there is a need for emergency surgery or invasive medical procedure. Kcentra is for use in adults and dosing is based on body weight ... Kcentra is contraindicated in patients with known anaphylactic or severe systemic reactions to Kcentra or any of its components (including heparin, Factors II, VII, IX, X, Proteins C and S, Antithrombin III and human albumin). Kcentra is also contraindicated in patients with disseminated intravascular coagulation.Kcentra was infused at a rate of 0.12 mL/kg/min, with a similar duration for matched placebo saline. Blood was collected for analysis of thrombin generation, anti‐factor Xa (anti‐Xa) activity, prothrombin time (PT) and activated partial thromboplastin time (PTT).Posted November 19, 2013. We are trying to utilize Kcentra and tranexamic acid here as part of our blood management program. We're thinking about Kcentra more for intracranial hemorrhages, and TXA for trauma/massive bleeds and knee replacements. I believe both will be used in trauma at some point.Nov 18, 2013 · Posted November 19, 2013. We are trying to utilize Kcentra and tranexamic acid here as part of our blood management program. We're thinking about Kcentra more for intracranial hemorrhages, and TXA for trauma/massive bleeds and knee replacements. I believe both will be used in trauma at some point. For example, a Kcentra® 500 unit vial can contain 400-620 units and a 1000 unit vial can contain 800-1240 units [5]. Most hospitals are required to bill based on exact units administered, so pharmacies often need to adjust Kcentra® orders to reflect the units that will be administered.Kcentra contains factors II, VII, IX, and X and Protein C and S and Bebulin contains factors II, IX, and X Both Bebulin and Kcentra are made from pooled human plasma 6. Riastap** Riastap is a human fibrinogen concentrate made from pooled human plasma and used to replace low or missing fibrinogen proteinMedical question support Kcentra Hotline representatives are trained to answer medical and treatment questions, which differentiates them from other hotlines that are strictly for product information and ordering/reimbursement support. Treating a patient and want to talk with a healthcare professional? Call the Kcentra Hotline at 1-855-452-3687KCENTRA is contraindicated in patients with known anaphylactic or severe systemic reactions to KCENTRA or any of its components (including heparin, Factors II, VII, IX, X, Proteins C and S, Antithrombin III and human albumin). KCENTRA is also contraindicated in patients with disseminated intravascular coagulation.Medical question support Kcentra Hotline representatives are trained to answer medical and treatment questions, which differentiates them from other hotlines that are strictly for product information and ordering/reimbursement support. Treating a patient and want to talk with a healthcare professional? Call the Kcentra Hotline at 1-855-452-3687Dec 4, 2017 · K-Centra contains trace amounts of heparin (to mitigate thrombotic potential) and should not be used in bleeding patients with active or recent (last 100 days) heparin-induced thrombocytopenia (HIT). In this instance, please contact pharmacy to discuss possible use of the alternative procoagulant FEIBA for reversal. rFVIIa (if refractory to ... Sleep is a swiftly reversible state of decreased metabolism, responsiveness and, motor activity, which is broadly categorized into rapid eye movement (REM) and non-rapid eye movement (NREM).[1] The NREM sleep phase again subdivides into stage N1, stage N2, and stage N3. The K-Complex is a waveform identified on electroencephalography (EEG), which primarily occurs during Stage 2 (N2) of NREM ...K-Centra contains trace amounts of heparin (to mitigate thrombotic potential) and should not be used in bleeding patients with active or recent (last 100 days) heparin-induced thrombocytopenia (HIT). In this instance, please contact pharmacy to discuss possible use of the alternative procoagulant FEIBA for reversal. rFVIIa (if refractory to ...KCENTRA ®, Prothrombin Complex Concentrate (Human), is a blood coagulation factor replacement product indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA—eg, warfarin) therapy in adult patients with acute major bleeding or the need for urgent surgery or other invasive procedure.• Administer Vitamin K concurrently to patients receiving Kcentra to maintain factor levels once the effects of Kcentra have diminished. • The safety and effectiveness of repeat dosing have not been established and it is not recommended. (2.1) • Administer reconstituted Kcentra at a rate of 0.12 mL/kg/min (~3 units/kg/min) up to(Kcentra) Clinical Recommendations for Use April 2015 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. KCENTRA is contraindicated in patients with known anaphylactic or severe systemic reactions to KCENTRA or any of its components (including heparin, Factors II, VII, IX, X, Proteins C and S, Antithrombin III and human albumin). KCENTRA is also contraindicated in patients with disseminated intravascular coagulation.Nov 13, 2019 · The change in INR before and after Kcentra® administration is shown in Figure 1. Thirty-seven (94.8%) patients included in the efficacy analysis achieved an INR measurement < 2 following Kcentra® administration. Twenty-eight (71.7%) of patients included in the efficacy analysis achieved an INR of < 1.7 following Kcentra® administration. KCENTRA is contraindicated in patients with known anaphylactic or severe systemic reactions to KCENTRA or any of its components (including heparin, Factors II, VII, IX, X, Proteins C and S, Antithrombin III and human albumin). KCENTRA is also contraindicated in patients with disseminated intravascular coagulation. Kcentra is a purified, heat-treated, nanofiltered, lyophilized, non-activated 4-factor prothrombin complex concentrate (4F-PCC) made from pooled human plasma. Kcentra contains all 4 vitamin–K dependent coagulation factors (II, VII, IX and X), and the antithrombotic Proteins C and S.380-800 units FII/500 units of Kcentra Non-activated form Units of FVII 10 ≤ 52.5 IU/mL (No more than 35 units/100 Factor IX units) -240 IU/mL 200-500 units FII/500 units of Kcentra Activated form Units of FIX 100-150 IU/mL 10-60 IU/mL 400-620 units FII/500 units of Kcentra Non-activated form Units of FXNov 29, 2018 · Retrospective analysis of inpatients at UPMC Presbyterian, Shadyside and Mercy, admitted between February 2016 and 2017 was done. A total of 213 patients, with history of stroke / DVT / PE who received Kcentra were grouped based on the cause of coagulopathy, sites of bleed (CNS or non-CNS) or the clinical setting of Kcentra administration. Dec 27, 2012 · Kcentra Marketing Approval Date: 12/13/2013 Approved Labeled Indication: Urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding or need for an urgent surgery/invasive procedure. Exclusivity End Date: Nov 18, 2021 · The primary outcome was coagulopathy reversal, defined as a post-Kcentra INR of This study included 31 patients with acute or chronic liver failure and 54 patients without liver failure. Both groups of patients were similar at baseline, except those that had liver failure were younger (58 vs 70 years, P < 0.01). K+K Hotel Central | Hybernská 10 | 110 00 Prague 1 | Czech Republic | [email protected] | +420 225 022 000. Art Nouveau architecture, elegant interiors, and superior service combine to make K+K Hotel Central the place to stay in Prague’s historic Old Town. K+K Hotel Central is one of the oldest Art Nouveau buildings in the city.Posted November 19, 2013. We are trying to utilize Kcentra and tranexamic acid here as part of our blood management program. We're thinking about Kcentra more for intracranial hemorrhages, and TXA for trauma/massive bleeds and knee replacements. I believe both will be used in trauma at some point.We would like to show you a description here but the site won’t allow us.We would like to show you a description here but the site won’t allow us. Kcentra is a 4 factor PCC from CSL Behring, containing non-activated factors II, VII, IX and X. The current FDA indications for Kcentra is for reversal of vitamin K dependent procoagulant factors II, VII, IX and X induced by oral vitamin K antagonists such as warfarin or coumadin. There are case reports of Kcentra use in FXa DOAC reversal. Obtain PT/INR/PTT prior to initiating Kcentra® and 2 hours after administration. Notes regarding Kcentra® dosing administration Each 500 unit vial contains 400 – 620 units factor IX. Pharmacy will enter the exact dose provide in factor IX units for billing purposes. Kcentra®should be infused through a separate infusion line.However, there is limited data on the efficacy and adverse effects of the commercial Kcentra used in these patients. Kcentra, the only approved PCC in the USA, is FDA approved for urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA) therapy in adult patients with acute major bleeding or need for an ...4-factor PCC (Kcentra) If INR 2-4: 25 units/kg (not to exceed 2500 units) If INR 4-6: 35 units/kg (not to exceed 3500 units) If INR > 6: 50 units/kg (not to exceed 5000 units) References: 1. Beshay JE, Morgan H, Madden C, Yu W, Sarode R. Emergency reversal of anticoagulation and antiplatelet therapies in neurosurgical patients. Jan 22, 2019 · In September 2018, the Pharmacy and Therapeutics Committee approved a new protocol for Emergent Vitamin K Antagonist (Warfarin) reversal via fixed dose Kcentra (PCC). We will go live with this protocol on January 22, 2019 . Kcentra contains factors II, VII, IX, and X and Protein C and S and Bebulin contains factors II, IX, and X Both Bebulin and Kcentra are made from pooled human plasma 6. Riastap** Riastap is a human fibrinogen concentrate made from pooled human plasma and used to replace low or missing fibrinogen protein5. Bebulin VH** (3 factor PCC) and Kcentra (4 factor PCC)** Kcentra is a prothrombin complex concentrate used to treat bleeding in patients with acquired coagulation factor deficiency induce by warfarin Bebulin is used to prevent and treat bleeding in patients with hemophilia B, congenital Factor IX deficiency or Christmas disease KCENTRA ®, Prothrombin Complex Concentrate (Human), is a blood coagulation factor replacement product indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA—eg, warfarin) therapy in adult patients with acute major bleeding or the need for urgent surgery or other invasive procedure ...Concentration: Final concentration in Factor IX units will range from 20–31 units/mL when reconstituted. Actual potency is listed on carton. If patient is to receive multiple vials, may pool contents; use a separate unused Mix2Vial transfer set for each vial. Administration should begin promptly or within 4 hrs of reconstitution.Kcentra is a purified, heat-treated, nanofiltered, lyophilized, non-activated 4-factor prothrombin complex concentrate (4F-PCC) made from pooled human plasma. Kcentra contains all 4 vitamin–K dependent coagulation factors (II, VII, IX and X), and the antithrombotic Proteins C and S.Storage of Kcentra after reconstitution: After reconstitution, administer immediately or within 4 hours. Reconstituted Kcentra can be stored at 2 to 25 degrees C (36 to 77 degrees F). If cooled, warm to 20 to 25 degrees C (68 to 77 degrees F) prior to administration. Do not freeze. Each vial contains no preservatives and is for single use only. Mar 7, 2015 · Figure 1. The vitamin K cycle and its link to carboxylation of glutamic acid residues on vitamin K–dependent coagulation proteins. Vitamin K 1 obtained from food sources is reduced to vitamin KH 2 by a warfarin-resistant vitamin K reductase. KCENTRA is contraindicated in patients with known anaphylactic or severe systemic reactions to KCENTRA or any of its components (including heparin, Factors II, VII, IX, X, Proteins C and S, Antithrombin III and human albumin). KCENTRA is also contraindicated in patients with disseminated intravascular coagulation.
(Kcentra) Clinical Recommendations for Use April 2015 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. . Abn amro
www.CSLBehring-us.com www.Kcentra.com US-KCT-0012 3/2017 Kcentra Administration Reminders Do not mix Kcentra with other medicinal products, and administer Kcentra through a separate infusion line Administer Kcentra at room temperature Administer Kcentra by intravenous infusion at a rate of 0.12 mL/kg/minKCENTRA is contraindicated in patients with known anaphylactic or severe systemic reactions to KCENTRA or any of its components (including heparin, Factors II, VII, IX, X, Proteins C and S, Antithrombin III and human albumin). KCENTRA is also contraindicated in patients with disseminated intravascular coagulation. Kcentra is a 4-factor prothrombin complex concentrate containing four vitamin K-dependent factors: Factor II (prothrombin), Factor VII, Factor IX and Factor X, as well as antithrombotic Proteins C and S. Kcentra is specifically indicated for for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA ...flushing (sudden warmth, redness, or tingly feeling); low red blood cells (anemia) --pale skin, unusual tiredness, feeling light-headed or short of breath, cold hands and feet; signs of a stroke ...Posted November 19, 2013. We are trying to utilize Kcentra and tranexamic acid here as part of our blood management program. We're thinking about Kcentra more for intracranial hemorrhages, and TXA for trauma/massive bleeds and knee replacements. I believe both will be used in trauma at some point.KCENTRA is contraindicated in patients with known anaphylactic or severe systemic reactions to KCENTRA or any of its components (including heparin, Factors II, VII, IX, X, Proteins C and S, Antithrombin III and human albumin). KCENTRA is also contraindicated in patients with disseminated intravascular coagulation. Individuals using assistive technology may not be able to fully access the information contained in this file. For assistance, please call 800-835-4709 or 240-402-8010, extension 1. KCENTRA is contraindicated in patients with known anaphylactic or severe systemic reactions to KCENTRA or any of its components (including heparin, Factors II, VII, IX, X, Proteins C and S, Antithrombin III and human albumin). KCENTRA is also contraindicated in patients with disseminated intravascular coagulation.Kcentra Speak with a Kcentra Hotline 1-855-4KCENTRA (1-855-452-3687) Hotline TOLL-FREE: www.Kcentra.com 7. Place the Kcentra vial on an even and fi rm surface. Invert the diluent vial with the Mix2Vial set attached and push the spike of the transparent adapter end straight down through the Kcentra vial stopper. The diluent will automatically fl ... Call the Kcentra Hotline at 1-855-452-3687; Adverse reactions: If your patient is having an adverse reaction to Kcentra, contact or have them contact CSL Behring Pharmacovigilance at 1-866-915-6958. For any other concern related to treatment with Kcentra, you can call the Kcentra Hotline at 1-855-452-3687 to speak with them about how to proceed However, there is limited data on the efficacy and adverse effects of the commercial Kcentra used in these patients. Kcentra, the only approved PCC in the USA, is FDA approved for urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA) therapy in adult patients with acute major bleeding or need for an ...Dosing: 20 to 50 units/kg, do not exceed 2500 to 5000 units. Dosage forms: Kcentra is available as a single-use vial containing coagulation factors II, VII, IX and X, and antithrombotic proteins C and S as a lyophilized concentrate. Adverse events: The most common adverse reactions (frequency ≥2.8%) observed in subjects receiving Kcentra were ...Kcentra is preferred over a fresh frozen plasma infusion because of its smaller volume, faster infusion rate, and superior effectiveness in INR reduction. For nonmajor bleeding (defined as any ....